RT Journal Article SR Electronic T1 Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.05.16.20104141 DO 10.1101/2020.05.16.20104141 A1 Juan Macías A1 Paz González-Moreno A1 Esther Sánchez-García A1 Ramón Morillo-Verdugo A1 Carmen Domínguez-Quesada A1 Ana Pinilla A1 MªMar Macho A1 MªVictoria Martínez A1 Alejandro González-Serna A1 Anaïs Corma A1 Luis M. Real A1 Juan A. Pineda YR 2020 UL http://medrxiv.org/content/early/2020/05/20/2020.05.16.20104141.abstract AB Background Hydroxychloroquine is currently being tested as post-exposure prophylaxis against coronavirus disease 2019 (COVID-19) in several ongoing clinical trials.Objective To compare the incidence of COVID-19 in Spanish patients with autoimmune rheumatic diseases treated with and without hydroxychloroquine.Methods Retrospective electronic record review, from February 27th to April 16th, of patients with autoimmune inflammatory diseases followed at two academic tertiary care hospitals in Seville, Spain. The cumulative incidence of COVID-19, confirmed or suspected, was compared between patients with and without hydroxychloroquine as part of their treatment of autoimmune inflammatory diseases.Results Among 722 included subjects, 290 (40%) were receiving hydroxychloroquine.During the seven-week study period, five (1.7%[95% CI: 0.5%–4.0%] cases of COVID-19 were registered among patients with hydroxychloroquine and five (1.2%[0.4%2.7%])(p=0.523) in without hydroxychloroquine. COVID-19 was confirmed by PCR in one (0.3%, 95% CI 0.008-1.9%) patient with hydroxychloroquine and two(0.5%,95% CI 0.05%–1.6%) without hydroxychloroquine (p=1.0). One patient on hydroxychloroquine and two subjects without hydroxychloroquine were admitted to the hospital, none of them required to be transferred to the intensive care unit and no patient died during the episode.Conclusions The incidence and severity of COVID-19 among patients with autoimmune rheumatic diseases with and without hydroxychloroquine was not significantly different. Hydroxychloroquine does not seem to be an appropriate therapy for post-exposure prophylaxis against COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementNot fundedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data could be accessed if requested